What is Northland Capmk’s Forecast for BLFS Q3 Earnings?

BioLife Solutions, Inc. (NASDAQ:BLFS) – Stock analysts at Northland Capmk increased their Q3 2025 earnings per share (EPS) estimates for shares of BioLife Solutions in a research report issued to clients and investors on Monday, March 3rd. Northland Capmk analyst C. Byrnes now forecasts that the medical equipment provider will earn $0.00 per share for the quarter, up from their previous forecast of ($0.01). The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. Northland Capmk also issued estimates for BioLife Solutions’ Q4 2025 earnings at $0.01 EPS.

Other equities analysts also recently issued reports about the stock. KeyCorp upped their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. TD Cowen upped their price target on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Northland Securities lifted their price objective on BioLife Solutions from $28.00 to $31.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 8th. Craig Hallum upped their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Finally, HC Wainwright cut their price target on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $29.43.

BioLife Solutions Trading Up 1.3 %

NASDAQ:BLFS opened at $24.84 on Wednesday. The firm has a market capitalization of $1.15 billion, a P/E ratio of -23.43 and a beta of 1.91. BioLife Solutions has a 52 week low of $14.84 and a 52 week high of $29.55. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a fifty day moving average of $26.71 and a 200 day moving average of $25.49.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The firm had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same quarter in the prior year, the firm posted ($0.21) earnings per share.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new position in BioLife Solutions in the 4th quarter worth approximately $26,000. Mark Sheptoff Financial Planning LLC bought a new position in shares of BioLife Solutions during the third quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of BioLife Solutions during the fourth quarter valued at $31,000. Quest Partners LLC purchased a new stake in shares of BioLife Solutions during the third quarter valued at $57,000. Finally, 1620 Investment Advisors Inc. raised its position in BioLife Solutions by 41.7% in the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after buying an additional 675 shares during the last quarter. Institutional investors own 93.24% of the company’s stock.

Insider Buying and Selling

In other news, CFO Troy Wichterman sold 987 shares of the stock in a transaction on Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at approximately $3,290,468.58. This represents a 0.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Aby J. Mathew sold 7,604 shares of the firm’s stock in a transaction on Monday, December 16th. The shares were sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. The trade was a 2.68 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,009 shares of company stock valued at $272,594 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.